

Biotechnology

Agios Pharmaceuticals Inc

Equity Research

January 16, 2014

Price: \$42.19 (01/15/2014)

Price Target: NA

OUTPERFORM (1)

Nicholas Bishop, Ph.D.

646.562.1378 nicholas.bishop@cowen.com

Eric Schmidt, Ph.D.

646.562.1345 eric.schmidt@cowen.com

Key Data

Symbol NASDAQ: AGIO
Market Cap (MM) \$1,315.1

Company Quick Take

Agios Shares On A Tear

The Cowen Insight

Agios shares have gained over 50% in the last 3 days and over 75% YTD. We have been fielding many inbound inquiries on this move, and are taking this opportunity to refresh investors on the story. Our detailed initiation report and models are linked below.


Agios is developing medicines targeting metabolic pathways that are altered in cancer or orphan disease. Though nothing has materially changed in the Agios story since the preclinical presentations at ASH last month (see our note), investors in search of good 2014 positions appear to have seized on Agios in recent days. Indeed, 2014 could be a transformational year for Agios, with: (1) lead candidate AG-221 for IDH2 mutant liquid tumors expected to produce Phase I proof of concept data during the year; (2) AG-120 for IDH1 mutant cancer to enter Phase I early in 2014 and possibly producing proof of concept data in late 2014 or 2015; and (3) AG-348 for the orphan disease PK deficiency to enter Phase I mid-year give proof of concept data in late 2014 or 2015.

All of these programs use Agios' precision medicine approach: they are targeted at clearly defined patient populations and influence a biomarker that is mechanistically tied to the desired activity. In this way, it should rapidly become apparent whether each drug is working as intended, likely in the first in human trials. Full details on Agios' programs are available in our initiation report (here).

We believe all Agios' programs carry a high chance of clinical success with a potentially short development path to access multi-hundred million dollar revenue opportunities. We expect AGIO to achieve a multi-billion dollar market cap over time and believe shares remain attractive over the long term, despite the recent move.

Agios Pharmaceuticals Inc

January 16, 2014



Valuation Methodology

Biotechnology:

In calculating our 12-month target price, we employ one or more valuation methodologies, which include a discounted earnings analysis, discounted cash flow analysis, net present value analysis and/or a comparable company analysis. These analyses may or may not require the use of objective measures such as price-to-earnings or price-to-sales multiples as well as subjective measures such as discount rates.

We make investment recommendations on early stage (pre-commercial) biotechnology companies based upon an assessment of their technology, the probability of pipeline success, and the potential market opportunity in the event of success. However, because these companies lack traditional financial metrics, we do not believe there are any good methodologies for assigning a specific target price to such stocks.

Investment Risks

Biotechnology:

There are multiple risks that are inherent with an investment in the biotechnology sector. Beyond systemic risk, there is also clinical, regulatory, and commercial risk. Additionally, biotechnology companies require significant amounts of capital in order to develop their clinical programs. The capital-raising environment is always changing and there is risk that necessary capital to complete development may not be readily available.


Risks To The Price Target

Agios Pharmaceuticals is developing several, currently preclinical, drug candidates in the areas of cancer metabolism and inborn errors of metabolism. All of Agios' drug candidates face clinical and regualtory risk. With the future development path depending on the evolution of clinical data, future revenue forecasts are uncertain. The commercial outlook for Agios' candidates could additionally be altered by safety/efficacy findings, emerging competition, alterations in the medical treatment paradigm, or changes in the pricing environment. Some of Agios' projected market exclusivity depends on patents, which are subject to challenge by generic drugmakers.

2

Equity Research

January 16, 2014



Stocks Mentioned In Important Disclosures

Ticker	Company Name
AGIO	Agios Pharmaceuticals Inc

Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

Cowen and Company, LLC and or its affiliates make a market in the stock of Agios Pharmaceuticals Inc securities.

Agios Pharmaceuticals Inc has been client(s) of Cowen and Company, LLC in the past 12 months.

Agios Pharmaceuticals Inc is or was in the past 12 months a client of Cowen and Company, LLC; during the past 12 months, Cowen and Company, LLC provided IB services.

Cowen and Company, LLC and/or its affiliates received in the past 12 months compensation for investment banking services from Agios Pharmaceuticals Inc.

Cowen and Company, LLC and/or its affiliates managed or co-managed a public offering of Agios Pharmaceuticals Inc within the past twelve months.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

Disclaimer

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research can be obtained on the Firm's client website, https://cowenlibrary.bluematrix.com/client/library.jsp.

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure website at https://cowen.bluematrix.com/sellside/Disclosures.action.

Price Targets: Cowen and Company, LLC assigns price targets on all covered companies unless noted otherwise. The price target for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. The price targets in this report should be considered in the context of all prior published Cowen and Company, LLC research reports (including the disclosures in any such report or on the Firm's disclosure website), which may or may not include price targets, as well as developments relating to the issuer, its industry and the financial markets. For price target valuation methodology and risks associated with the achievement of any given price target, please see the analyst's research report publishing such targets.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Copyright, User Agreement and other general information related to this report

© 2013 Cowen and Company, LLC. Member NYSE, FINRA and SIPC. All rights reserved. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets). All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

Cowen and Company, LLC. New York (646) 562-1000 Boston (617) 946-3700 San Francisco (415) 646-7200 Chicago (312) 577-2240 Cleveland (440) 331-3531 Atlanta (866) 544-7009 London (affiliate) 44-207-071-7500

COWEN AND COMPANY RATING DEFINITIONS

Cowen and Company Rating System effective May 25, 2013

Outperform (1): The stock is expected to achieve a total positive return of at least 15% over the next 12 months

Market Perform (2): The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

Underperform (3): Stock is expected to achieve a total negative return of at least 10% over the next 12 months

Assumption: The expected total return calculation includes anticipated dividend yield

Cowen and Company Rating System until May 25, 2013

Outperform (1): Stock expected to outperform the S&P 500

Neutral (2): Stock expected to perform in line with the S&P 500

Underperform (3): Stock expected to underperform the S&P 500

Assumptions: Time horizon is 12 months; S&P 500 is flat over forecast period

Cowen Securities, formerly known as Dahlman Rose & Company, Rating System until May 25, 2013

Buy – The fundamentals/valuations of the subject company are improving and the investment return is expected to be 5 to 15 percentage points higher than the general market return

www.cowen.com

Agios Pharmaceuticals Inc

January 16, 2014

Equity Research

Sell – The fundamentals/valuations of the subject company are deteriorating and the investment return is expected to be 5 to 15 percentage points lower than the general market return

Hold – The fundamentals/valuations of the subject company are neither improving nor deteriorating and the investment return is expected to be in line with the general market return

Cowen And Company Rating Definitions

Distribution of Ratings/Investment Banking Services (IB) as of 12/31/13


Rating	Count	Ratings Distribution	Count	IB Services/Past 12 Months
Buy (a)	415	59.20%	68	16.39%
Hold (b)	270	38.52%	4	1.48%
Sell (c)	16	2.28%	1	6.25%

(a) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions. (b) Corresponds to "Market Perform" as defined in Cowen and Company, LLC's ratings definitions. (c) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions.

Note: "Buy", "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA and NYSE regulations.

Agios Pharmaceuticals Inc Rating History as of 01/15/2014

powered by: BlueMatrix



Legend for Price Chart:

I = Initation | 1 = Outperform | 2 = Market Perform | 3 = Underperform | UR = Price Target Under Review | T = Terminated Coverage | \$xx = Price Target | NA = Not Available

Target Price

Closing Price

Equity Research

Agios Pharmaceuticals Inc

January 16, 2014

Points Of Contact

Reaching Cowen

Main U.S. Locations

New York

599 Lexington Avenue New York, NY 10022 646.562.1000 800.221.5616

Atlanta

3399 Peachtree Road NE Suite 417 Atlanta, GA 30326 866.544.7009

Boston

Two International Place Boston, MA 02110 617.946.3700 800.343.7068

Cleveland

20006 Detroit Road Suite 100 Rocky River, OH 44116 440.331.3531

San Francisco

555 California Street, 5th Floor San Francisco, CA 94104 415.646.7200 800.858.9316

Chicago

181 West Madison Street Suite 1925 Chicago, IL 60602 312.577.2240

International Locations

Cowen International Limited

London

1 Snowden Street - 11th Floor London EC2A 2DQ United Kingdom 44.20.7071.7500

Cowen and Company (Asia) Limited

Hong Kong

Suite 1401 Henley Building No. 5 Queens Road Central Central, Hong Kong 852 3752 2333







www.cowen.com